US Capitol Capsule: White House Medicare Rx horse trading pays off
This article was originally published in Scrip
Last summer, the White House was highly criticized for the behind-the-scenes wheeling and dealing it conducted in 2009 with the biopharmaceutical industry and other health care sectors over what eventually became the Affordable Care Act (ACA). But those negotiations four years ago resulted in a deal that has paid off in a big way – with Medicare beneficiaries enrolled in the Part D prescription drug program saving a total of $2.5 billion last year on branded medicines, with another 2.8 million seniors and disabled Americans garnering $105 million in discounts for generics.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.